Optimer Pharm upgraded following enrollment completion at Oppenheimer
As reported earlier, Oppenheimer upgraded Optimer Pharmaceuticals to Outperform from Perform. The firm upgraded shares after the company announced the enrollment completion of the second fidaxomicin Phase III trial. Opco's target on shares is $16. :theflyonthewall.com
News For OPTR From The Last 14 Days
Check below for free stories on OPTR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
